Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
在HER2+/PD-L1+不可切除或转移性胃食管腺癌中,Margetuximab联合retifanlimab作为一线治疗:MAHOGANY队列A
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2022.100563
Catenacci, D V T; Kang, Y-K; Yoon, H H; Shim, B Y; Kim, S T; Oh, D-Y; Spira, A I; Ulahannan, S V; Avery, E J; Boland, P M; Chao, J; Chung, H C; Gardner, F; Klempner, S J; Lee, K-W; Oh, S C; Peguero, J; Sonbol, M B; Shen, L; Moehler, M; Sun, J; Li, D; Rosales, M K; Park, H